EuroEspes S.A (EEP) | Financial Analysis & Statements
EuroEspes S.A. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Income Metrics
Balance Sheet Metrics
Total Assets
10.2M
Total Liabilities
4.0M
Shareholders Equity
6.2M
Debt to Equity
0.65
Cash Flow Metrics
Revenue & Profitability Trend
Annual Income Flow
2024
EuroEspes S.A Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 2.9M | 3.0M | 3.3M | 3.3M | 2.5M |
| Cost of Goods Sold | 340.1K | 242.8K | 217.2K | 101.8K | 141.0K |
| Gross Profit | 2.6M | 2.7M | 3.1M | 3.2M | 2.4M |
| Gross Margin % | 88.3% | 91.8% | 93.4% | 96.9% | 94.4% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | - | - | 1.4M | 1.0M | 623.1K |
| Other Operating Expenses | 921.5K | 1.6M | 1.6M | 1.2M | 753.6K |
| Total Operating Expenses | 921.5K | 1.6M | 2.9M | 2.2M | 1.4M |
| Operating Income | -270.5K | -1.4M | -956.6K | -247.4K | -351.0K |
| Operating Margin % | -9.3% | -47.6% | -29.0% | -7.5% | -13.9% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | 154.7K | 21 |
| Interest Expense | 42.3K | 220.9K | 103.8K | 94.8K | 82.9K |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | -319.3K | -2.1M | -1.2M | -177.0K | -429.5K |
| Income Tax | 3.9K | - | - | 6.5K | -18.1K |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -323.2K | -2.1M | -1.2M | -183.4K | -411.3K |
| Net Margin % | -11.1% | -72.3% | -35.3% | -5.6% | -16.3% |
| Key Metrics | |||||
| EBITDA | 467.4K | -408.3K | -102.2K | 510.9K | 229.7K |
| EPS (Basic) | - | - | €-0.10 | €-0.02 | €-0.04 |
| EPS (Diluted) | - | - | €-0.10 | €-0.02 | €-0.04 |
| Basic Shares Outstanding | - | - | 11608566 | 11597984 | 11573296 |
| Diluted Shares Outstanding | - | - | 11608566 | 11597984 | 11573296 |
Income Statement Trend
EuroEspes S.A Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 217.4K | 422.9K | 971.1K | 2.0M | 2.2M |
| Short-term Investments | 370 | 2.5K | 2.5K | 17.2K | 17.6K |
| Accounts Receivable | 116.3K | 248.0K | 374.1K | 322.1K | 183.5K |
| Inventory | 272.1K | 342.8K | 475.0K | 549.8K | 431.6K |
| Other Current Assets | - | - | - | - | - |
| Total Current Assets | 631.8K | 1.1M | 2.0M | 2.9M | 3.0M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 10.4M | 10.4M | 10.5M | 10.0M | 9.9M |
| Goodwill | 2.6M | 3.0M | 3.6M | 4.0M | 3.8M |
| Intangible Assets | 2.6M | 3.0M | 3.6M | 4.0M | 3.8M |
| Long-term Investments | 0 | 0 | 9.9K | 15.0K | 0 |
| Other Non-Current Assets | - | -151 | - | 1 | - |
| Total Non-Current Assets | 6.3M | 6.9M | 8.3M | 9.3M | 8.7M |
| Total Assets | 6.9M | 7.9M | 10.2M | 12.3M | 11.7M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 104.4K | 117.1K | 179.2K | 165.8K | 218.6K |
| Short-term Debt | 185.5K | 4.0M | 1.8M | 810.5K | 859.6K |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 681.4K | 5.0M | 2.6M | 1.6M | 1.4M |
| Non-Current Liabilities | |||||
| Long-term Debt | 3.3M | 28.1K | 2.6M | 3.2M | 2.8M |
| Deferred Tax Liabilities | 3.2K | 2.7K | 3.0K | 3.6K | 5.0K |
| Other Non-Current Liabilities | - | - | -1.2M | - | - |
| Total Non-Current Liabilities | 3.7M | 44.6K | 2.7M | 3.3M | 2.9M |
| Total Liabilities | 4.4M | 5.0M | 5.2M | 4.8M | 4.3M |
| Equity | |||||
| Common Stock | 7.1M | 7.1M | 7.1M | 7.1M | 7.1M |
| Retained Earnings | -323.2K | -2.1M | -1.2M | -183.4K | -411.3K |
| Treasury Stock | 143.2K | 143.2K | 110.9K | 107.6K | 151.2K |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 2.6M | 2.9M | 5.0M | 7.4M | 7.4M |
| Key Metrics | |||||
| Total Debt | 3.5M | 4.0M | 4.4M | 4.0M | 3.6M |
| Working Capital | -49.6K | -3.9M | -586.2K | 1.4M | 1.6M |
Balance Sheet Composition
EuroEspes S.A Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -319.3K | -2.1M | -1.2M | -177.0K | -429.5K |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | -175.4K | 899.9K | -236.9K | -277.1K | -216.0K |
| Operating Cash Flow | -453.0K | -1.0M | -2.2M | -1.1M | -825.0K |
| Investing Activities | |||||
| Capital Expenditures | -1.8K | -167.4K | -554.8K | -94.1K | -60.3K |
| Acquisitions | 2.3K | - | - | - | - |
| Investment Purchases | -99.9K | -557.5K | 0 | -560.0K | 0 |
| Investment Sales | 4.5K | 10.1K | - | - | - |
| Investing Cash Flow | -95.0K | -714.8K | -554.8K | -654.1K | -60.3K |
| Financing Activities | |||||
| Share Repurchases | - | -34.2K | -101.9K | -152.3K | -85.6K |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 388.2K | 57.6K | 995.6K | 1.0M | 1.5M |
| Debt Repayment | -370.6K | -57.0K | -634.9K | -687.5K | -1.2M |
| Financing Cash Flow | 17.6K | -33.6K | 364.7K | 491.0K | 312.8K |
| Free Cash Flow | -130.0K | 32.8K | -1.4M | -184.1K | -429.9K |
| Net Change in Cash | -530.3K | -1.8M | -2.4M | -1.2M | -572.5K |
Cash Flow Trend
EuroEspes S.A Key Financial Ratios
Valuation Ratios
Price to Sales
2.14
Profitability Ratios
Profit Margin
88.31%
Operating Margin
-9.52%
Return on Equity
-12.57%
Return on Assets
-4.65%
Financial Health
Current Ratio
0.77
Debt to Equity
0.70
Per Share Data
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| EEP | 6.2M | - | - | -12.57% | 88.31% | 0.70 |
| Clinica Baviera S.A | 833.0M | 19.77 | 7.57 | 41.02% | 13.80% | 62.33 |
| Pangaea Oncology | 61.8M | -50.34 | 3.07 | -29.97% | -37.18% | 23.04 |
| Grifols, S.A | 6.1B | 15.58 | 1.19 | 6.17% | 5.34% | 126.83 |
| Laboratorios | 4.3B | 36.12 | 6.59 | 22.33% | 18.89% | 18.04 |
| Almirall S.A | 2.8B | 58.64 | 1.86 | 3.10% | 4.14% | 23.30 |
Financial data is updated regularly. All figures are in the company's reporting currency.





